home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Organon & Co. Common Stock (NY:OGN)

6.340 -0.010 (-0.16%)

Official Closing Price Updated: 7:00 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Europe's Unicorns ↗

October 15, 2021

After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit.

Via Talk Markets

Organon Launches New Fertility Journey Website as Part of Ongoing Commitment to Help Address the Needs of Women

October 15, 2021

From Organon & Co.

Via Business Wire

Organon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum Hemorrhage

October 11, 2021

From Organon & Co.

Via Business Wire

Expert Ratings For Organon ↗

October 07, 2021

Analysts have provided the following ratings for Organon (NYSE:OGN) within th...

Via Benzinga

What 6 Analyst Ratings Have To Say About Organon ↗

September 01, 2021

Organon (NYSE:OGN) has observed the following analyst ratings within the last...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗

October 07, 2021

Upgrades For State Street Corporation (NYSE:

Via Benzinga

Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy

September 21, 2021

From Organon & Co.

Via Business Wire

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗

August 08, 2021

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...

Via Benzinga

Unusual Options Activity Insight: UP Fintech Holding ↗

July 30, 2021

Organon (NYSE:OGN) shares experienced unusual options activi...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021 ↗

September 01, 2021

Upgrades For Chatham Lodging Trust (NYSE:

Via Benzinga

Organon To Present at Morgan Stanley’s 19th Annual Global Healthcare Virtual Conference

September 01, 2021

From Organon & Co.

Via Business Wire

Organon To Present at Citi’s 16th Annual BioPharma Virtual Conference

September 01, 2021

From Organon & Co.

Via Business Wire

Top Stocks Warren Buffett Just Bought ↗

August 18, 2021

These were Berkshire Hathaway's biggest buys during Q2, 2021.

Via The Motley Fool

Friday the Thirteenth ↗

August 13, 2021

The stock week in points eastward was mixed. The USA markets face a bear correction.

Via Talk Markets

Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios ↗

August 17, 2021

The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and...

Via Benzinga

Merck Spinoff Organon Just Reported Its First Quarter — Here's What You Need To Know ↗

August 12, 2021

Organon crushed Wall Street's second-quarter expectations on Thursday and announced its first dividend, leading OGN stock to pop.

Via Investor's Business Daily

Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend

August 12, 2021

From Organon & Co.

Via Business Wire

ObsEva Stock Surges On Potential $500M Ebopiprant Deal For Preterm Labor ↗

July 27, 2021

Organon & Co (NYSE: OGN) will license the global development, manufacturing, and commercial rights to ObsEva SA's (NASDAQ: OBSV) ebopiprant (OBE022)...

Via Benzinga

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor

July 27, 2021

From Organon

Via Business Wire

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗

August 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...

Via Benzinga

Earnings Scheduled For August 12, 2021 ↗

August 12, 2021

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...

Via Benzinga

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021 ↗

July 23, 2021

Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS...

Via Benzinga

Joblessness Surprise ↗

July 22, 2021

Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021 ↗

July 22, 2021

Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:...

Via Benzinga

Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

July 22, 2021

From Organon & Co.

Via Business Wire

Why Ocugen Shares Are Rallying Today ↗

July 15, 2021

Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling...

Via Benzinga

3 Stocks I'd Avoid at All Costs ↗

July 13, 2021

On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away.

Via The Motley Fool

Stay Away From Low-Growth Organon ↗

July 08, 2021

Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive.

Via InvestorPlace

Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

June 29, 2021

From Organon & Co.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com